TipRanks on MSN

Ensysce Biosciences CEO says 'positioned for continued momentum'

Ensysce Biosciences (ENSC) issued its 2025 annual letter to shareholders from CEO Lynn Kirkpatrick, which read in part, “2025 was a year of ...
Seeking Alpha

Mercury Systems: Lack Of Margin Of Safety Makes Me Stay Neutral

I am neutral on Mercury Systems due to strong turnaround momentum but a valuation that leaves little margin for error. MRCY is well-positioned for a multi-year ...

Vizsla Silver: Exploration Risk Is Gone, But Execution Risk Remains

Vizsla Silver is a late-stage, pre-revenue silver developer advancing the Panuco project in Mexico, targeting production in ...

PhaseV Closes 2025 with Record Growth, Supporting Biopharma's Shift from AI Pilots to Full-Scale Execution

BOSTON, Dec. 16, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML for clinical development, today announced key milestones for 2025 that confirm its transition from a high-growth startup to an ...